David W. Denning MBBS, FRCP, FRCPath, DCH, FMedSci
David is the Professor of Infectious Diseases in Global Health and Consultant in Infectious Diseases and Medical Mycology, Wythenshawe Hospital and University of Manchester and President of the Global Action Fund for Fungal Infections. He Graduates of Guy's Hospital, University of London, 1980. His clinical training in internal medicine, infectious diseases, microbiology, pediatrics and hematology in London, Glasgow, and California (1980-1990). His research training at the MRC Clinical Research Center, Harrow, UK (1985-87) and Stanford University, California, USA (1987-1990). Granted a personal chair by Manchester University in 2005.
His clinical interests are in fungal diseases, immunocompromised patients and complex hospital infection problems. His research interests relate to antifungal susceptibility testing and resistance, the pathogenesis of invasive aspergillosis, clinical studies of antifungal agents, Aspergillus genomics and the burden of fungal infections globally and in different countries.
In addition to continuing clinical practice and research, he was instrumental in starting a biotechnology company called F2G. F2G has identified several new promising antifungal drug candidates, one of which is short to be studied in human volunteers. he retains a very small number of F2G shares, but no longer consult for it.